Inspira Therapeutics, Inc

Gainesville, FL · Founded 2020 · CIK 0001941581 · Biotech · Private

In vivo tolerogenic vaccine using dendritic cell engineering to restore immune tolerance in autoimmune diseases

inspiratherapeutics.com →
Grants
$3.0M
2 awards
Sector median: 1
Raised
—
1 Form D · Aug 2022
50 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · A polymeric biomaterial-based vaccine utilizing immunomodulatory agents and antigen for the amelioration of type 1 diabetes.$1,982,936
Federal grantDepartment of Health and Human Services · Phase II · A polymeric biomaterial-based vaccine utilizing immunomodulatory agents and antigen for the amelioration of type 1 diabetes.$993,629
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3374Aqualung Therapeutics Corp.—$3.1M
3375Concerto Biosciences, Inc.—$16M
3376UNCO THERAPEUTICS LLC——
3377Inspira Therapeutics, Inc——
3378SYGNAMAP, INC.——
3379Polyrizon Ltd.—$7.5M
3380BlossomHill Therapeutics—$246M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Anne FavreDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.